Takeda Pharmaceutical Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Net-Interest-Income" stands at -139.34 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 09/30/2024.
Takeda Pharmaceutical Co. Ltd.'s second quarter result of -38.74 Billion JPY for the item "Net Interest Income" represents a decrease of -15.99 percent compared to it's first quarter result.
Also, Takeda Pharmaceutical Co. Ltd.'s second quarter result of -38.74 Billion JPY for the item "Net Interest Income" represents an increase of 39.78 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Takeda Pharmaceutical Co. Ltd.'s second quarter result of -139.34 Billion JPY for the item "Net Interest Income" represents an increase of 15.52 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 12.69 Billion Japanese Yens compared to the value the year prior.
The 1 year change is 12.69 Billion Japanese Yens.
The 3 year change is -20.90 Billion Japanese Yens.
The 5 year change is 6.50 Billion Japanese Yens.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Interest Income | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Interest Income | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Interest Income | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Interest Income | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Interest Income | 280,205,508,085.11 |